Shared insight from expert oncologists on key clinical trial data in lymphomas from the ASCO 2022 and EHA 2022 Annual Meetings.
Kieron Dunleavy, MD
Advertisement
Articles by Kieron Dunleavy, MD
Expert oncologist perspectives on key clinical trial data in acute lymphocytic leukemia from the ASCO 2022 and EHA 2022 Annual Meetings.
Dr. Kieron Dunleavy, from the National Cancer Institute, Discusses Treatment Options for Primary Mediastinal B Cell Lymphoma
Dr. Kieron Dunleavy, from the National Cancer Institute, Discusses ABC DLBCL Research
Dr. Kieron Dunleavy from the National Cancer Institute Discusses 3 Molecular Subtypes of DLBCL
Advertisement
Latest Updated Articles
Dr. Dunleavy Discusses ABC DLBCL ResearchMarch 23rd 2012
Dr. Dunleavy Discusses Treatment Options for PMBLApril 16th 2012
Dr. Dunleavy Discusses 3 Molecular Subtypes of DLBCLFebruary 24th 2012
Advertisement
Advertisement
Trending on OncLive
1
Vopimetostat Plus Daraxonrasib Yields 92% ORR in MTAP-Deleted, RAS-Mutant Pancreatic Cancer
2
KEYNOTE-D46 Trial Is Discontinued With Sacituzumab Govitecan Plus Pembrolizumab in PD-L1–High NSCLC
3
GU Cancer Experts Highlight the Most Impactful and Discussion-Worthy Data Presented at ASCO 2026
4
Subcutaneous Isatuximab Administered Via OBI Approved in EU for Multiple Myeloma
5